New to Bioss? Enjoy 35% of your first order. Use code "FirstOrder35" - Offer valid for new U.S. Customers on direct orders only

ENTPD2/CD39L1 Polyclonal Antibody, Cy3 Conjugated

Applications

  • WB
  • IF(IHC-P)
  • IF(IHC-F)
  • IF(ICC)

Reactivity

  • Rat

Predicted Reactivity

  • Human
  • Mouse
  • Cow
  • Sheep
  • Chicken
Overview
Catalog # bs-11515R-Cy3
Product Name ENTPD2/CD39L1 Polyclonal Antibody, Cy3 Conjugated
Applications WB, IF(IHC-P), IF(IHC-F), IF(ICC)
Reactivity Rat
Predicted Reactivity Human, Mouse, Cow, Sheep, Chicken
Specifications
Conjugation Cy3
Host Rabbit
Source KLH conjugated synthetic peptide derived from human ENTPD2/CD39L1
Immunogen Range 401-495/495
Clonality Polyclonal
Isotype IgG
Concentration 1ug/ul
Purification Purified by Protein A.
Storage Buffer Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Storage Condition Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
Target
Subcellular location Cell membrane
Synonyms CD39 antigen like 1; CD39 antigen-like 1; CD39 like1; CD39L1; CD39like1; ecto ATP diphosphohydrolase 2; ecto ATPase 2; ecto ATPDase 2; Ecto-ATP diphosphohydrolase 2; Ecto-ATPase 2; Ecto-ATPDase 2; ectoATPase 2; ectoATPDase 2; Ectonucleoside triphosphate diphosphohydrolase 2; ENTP2_HUMAN; Entpd2; NTPDase 2; NTPDase2.
Background CD39, also known as ectonucleoside triphosphate diphosphohydrolase 1 (ENP1), is an integral membrane glycoprotein that acts as an extracellular nucleotide-hydrolyzing enzyme. CD39 inhibits ADP-induced platelet aggregation by hydrolyzing ADP to AMP and ultimately generating adenosine. Intracellular CD39 undergoes glycosylation at 6 N-glycosylation sites and translocates to the membrane in order to be an active enzyme. CD39L1 is a 495 amino acid multi-pass membrane protein that requires calcium and magnesium cofactors to hydrolyze ATP and other nucleotides in the regulation of purigenic neurotransmission. CD39L1 is expressed in kidney, colon, heart, testis, pancreas, brain, prostate, skeletal muscle, small intestine and ovaries. There are two isoforms of CD39L1 that are produced as a result of alternative splicing events.
Application Dilution
WB 1:300-5000
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200